Announcements Trials

Browse Landscape

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Breast 56 Gastrointestinal 42 Genitourinary 38 Head & Neck 28 Gynecologic 19 Tumor-Agnostic 17 Thoracic 16 Lymphoid 12 CNS 12 Other hematologic neoplasm 11 Sarcoma 8 Dermatologic 6 Plasma cell 5 Endocrine 4 Other solid neoplasm 3 Other 3 Other neoplasm 1 NET 1 Myeloid 1 Classical hematology 1

Conditions

Myeloproliferative Disorders 1

Interventions

fludarabine 63 Cyclophosphamide 63 venetoclax 57 Azacitidine 52 fludarabine phosphate 50 Specimen Handling 44 Whole-Body Irradiation 40 ruxolitinib 37 Mycophenolic Acid 37 Tacrolimus 35 Melphalan 32 Busulfan 32 Biopsy 32 Cytarabine 31 Stem Cell Transplantation 27 Decitabine 27 Granulocyte Colony-Stimulating Factor 21 asciminib 19 decitabine and cedazuridine drug combination 18 Sirolimus 18 Peripheral Blood Stem Cell Transplantation 18 Injections 18 Thiotepa 17 Filgrastim 17 nilotinib 15 X-Rays 14 Methotrexate 14 Cyclosporine 14 Imatinib Mesylate 13 Magnetic Resonance Spectroscopy 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Surveys and Questionnaires × Myeloid × 1 year × Clear all

NCT04378855 2025-09-23

PROPHECY

Gruppo Italiano Malattie EMatologiche dell'Adulto

Active not recruiting

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡